Efficiency ustekinumab in the treatment of patients with psoriasis with metabolic disorders

• Main Authors: I. V. Rychkova, O. A. Prytulo
• Format: Article
• Language: Russian
• Published: Remedium Group LLC 2019-08-01
• Series: Медицинский совет
• Subjects: psoriasis; metabolic syndrome; therapeutic efficacy; ustekinumab
• Online Access: https://www.med-sovet.pro/jour/article/view/3144

One of the goals of psoriasis therapy is to achieve sustainable remission. Currently, genetically engineered biological drugs are most effective in the treatment of psoriasis. However, there is a certain proportion of patients with insufficient efficiency of genetic engineering biological therapy. One of the reasons for reducing the therapeutic response in patients with psoriasis may be the presence of metabolic syndrome.Objective: to study the therapeutic efficacy of ustekinumab in patients with psoriasis with metabolic syndrome.Materials and methods: 52 patients with plaque psoriasis receiving ustekinumab therapy were observed: 25/52 (48.0%) patients with metabolic syndrome, 27/52 (52.0%) - without metabolic syndrome. The proportion of patients who reached PASI75 by the 12th week among patients with psoriasis with and without metabolic syndrome was 17/25 (68.0%) and 23/27 (85.2%) (p>0.05), respectively; 24th week - 15/25 (60.0%) and 25/27 (92.6%) (p<0.05), respectively; 48th week-14/25 (56.0%) and 24/27 (88.9%) (p<0.05).Conclusion: therapeutic efficacy of ustekinumab is higher in patients with psoriasis without metabolic syndrome than in patients with metabolic syndrome.